T1	Participants 36 81	recipients of extended criteria donor kidneys
T2	Participants 271 384	Patients who remained on assigned therapy through year 3 were eligible to enter a long-term extension (LTE) study
T3	Participants 386 465	Three hundred four patients entered the LTE (n = 104 MI; n = 113 LI; n = 87 CsA
T4	Participants 1073 1154	patients who were seronegative for Epstein-Barr virus (EBV(-)) at transplantation
